Aytu Biopharma (AYTU) Receivables (2015 - 2026)
Aytu Biopharma (AYTU) posted quarterly Receivables of $24.5 million for Q1 2026, down 38.97% year-over-year from $40.1 million in Q1 2025, and down 20.81% quarter-over-quarter from $30.9 million in Q4 2025.
Aytu Biopharma (AYTU) Receivables (2015 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Receivables for 12 consecutive years, with $24.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 38.97% year-over-year to $24.5 million; the TTM figure through Mar 2026 stood at $24.5 million (down 38.97% YoY), while the FY2025 annual figure was $35.4 million, up 12.35% from the prior year.
- Receivables retreated to $24.5 million in Q1 2026 per AYTU's latest filing, from $30.9 million in the prior quarter.
- Across five years, Receivables topped out at $40.1 million in Q1 2025 and bottomed at $24.2 million in Q2 2022.
- Historically, Receivables has averaged $30.2 million across 5 years, with a median of $29.9 million in 2023.
- Annual changes were most pronounced in 2025 — Receivables surged 34.2% — and 2026, when it slumped 38.97%.
- Aytu Biopharma's Receivables stood at $25.5 million in 2022, then increased by 15.29% to $29.4 million in 2023, then grew by 6.13% to $31.2 million in 2024, then fell by 0.9% to $30.9 million in 2025, then slipped by 20.81% to $24.5 million in 2026.
- Business Quant data shows AYTU's Receivables at $24.5 million in Q1 2026, $30.9 million in Q4 2025, and $33.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Aytu Biopharma | 24.54 Mn | -2.17 Mn | 7.60 Mn | 24.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.49 Mn |
| Dec 31, 2025 | 30.92 Mn |
| Sep 30, 2025 | 33.23 Mn |
| Jun 30, 2025 | 34.26 Mn |
| Mar 31, 2025 | 40.13 Mn |
| Dec 31, 2024 | 31.20 Mn |
| Sep 30, 2024 | 28.96 Mn |
| Jun 30, 2024 | 29.73 Mn |
| Mar 31, 2024 | 29.90 Mn |
| Dec 31, 2023 | 29.40 Mn |
| Sep 30, 2023 | 29.90 Mn |
| Jun 30, 2023 | 31.72 Mn |
| Mar 31, 2023 | 34.04 Mn |
| Dec 31, 2022 | 25.50 Mn |
| Sep 30, 2022 | 27.90 Mn |
| Jun 30, 2022 | 24.22 Mn |
| Mar 31, 2022 | 27.61 Mn |
| Dec 31, 2021 | 22.99 Mn |
| Sep 30, 2021 | 21.64 Mn |
| Jun 30, 2021 | 30.35 Mn |